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Abstract The aim of the present study was to evaluate
the efficacy of novel nonviral gene delivery systems in
cells of musculoskeletal origin. Primary cultures of lapine
skeletal muscle cells, lapine articular chondrocytes, human
cells from fibrous dysplasia and cell lines established from
human osteosarcoma (SAOS-2), chondrosarcoma (CS-1),
murine skeletal myoblasts (L8) and fibroblasts (NIH 3T3)
were transfected with the P. pyralis luc or the E. coli lacZ
genes using Nanofectin 1 and 2, Superfect, JetPEI, Gene-
Jammer, Effectene, TransPass D2, FuGENE 6, Lipofecta-
mine 2000, Dreamfect, Metafectene, Escort III, and
calcium phosphate. Maximal transfection efficiency in
lapine skeletal muscle cells was of 60.8 ± 21.2% using
Dreamfect, 38.9 ± 5.0% in articular chondrocytes using
Gene Jammer, 5.2 ± 8.0% in human cells from fibrous
dysplasia using Lipofectamine 2000, 12.7 ± 16.2% in
SAOS-2 cells using FuGENE 6, 29.9 ± 3.5% in CS-1 cells
using Lipofectamine 2000, 70.7 ± 8.6% in L8 cells using
FuGENE 6, and 48.9 ± 13.0% in NIH 3T3 cells using
Metafectene. When the cells were transfected with a
human IGF-I gene, significant amounts of the IGF-I protein
were secreted. These results indicate that relatively high
levels of transfection can be achieved using novel nonviral
gene transfer methods.
Keywords Gene transfer  Nonviral 
Musculoskeletal cells  IGF-I  Transfection efficiency
Introduction
Gene transfer to cells that constitute the musculoskeletal
system is a valuable tool for functional studies and possible
therapeutic applications such as gene-modified tissue
regeneration. Although it has been shown that these cells can
be transduced with viral vectors at high efficiencies [1], these
vectors carry the risk of insertional mutagenesis (retroviral
vectors), immunogenicity (adenoviral vectors) and acquisi-
tion of replication competence [1]. Nonviral gene delivery
systems are potent alternatives that may overcome such
crucial issues [2]. They usually do not provoke an immune
response, are relatively easy to manipulate and show no
limitation in the size of DNA to be delivered. Transfection of
articular chondrocytes and skeletal muscle cells has been
already reported using typical transfection methods [3, 4].
Recently, however, novel nonviral gene delivery systems
have been developed [2], including activated-dendrimer [5],
linear polyethylenimine [6], lipid- [7] and nanoparticle-
based compounds [8]. Although these new systems hold
promises to achieve high-transfection efficiencies, a sys-
tematic evaluation in a large variety of cells has not, to our
knowledge, been performed to date.
The aim of this study was to comparatively examine a
panel of novel nonviral compounds in both primary cells and
established cell lines from musculoskeletal origin. We tested
the hypothesis that, under optimized conditions, these gene
transfer systems are capable of yielding high transfection
efficiencies. We chose 13 systems that are based on nano-
particles, activated-dendrimers, linear polyethylenimines
and several lipid-based compounds and cationic liposomes.
All of them were tested in primary cultures of skeletal muscle
cells, articular chondrocytes, cells from fibrous dysplasia and
cell lines from osteosarcoma (SAOS-2), chondrosarcoma
(CS-1), myoblasts (L8) and fibroblasts (NIH 3T3). For each
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cell type, the transfection system promoting the highest
efficiency was next applied, in order to monitor the secretion
levels of the transgene product. For this purpose, a human
insulin-like growth factor I (IGF-I) plasmid expression
vector was used.
Materials and Methods
Materials
Reagents were from Invitrogen (Karlsruhe, Germany) unless
otherwise indicated. Plasticware was from Falcon (Beckton
Dickinson, Pont de Claix, France). For transfections, Nano-
fectin 1 and 2 (PAA, Pasching, Austria), Superfect (Qiagen,
Hilden, Germany), JetPEI (PolyPlus Transfection, Illkirch,
France), Escort III (Sigma, Taufkirchen, Germany), Gene
Jammer (Stratagene, La Jolla, CA), Effectene (Qiagen),
TransPass D2 (New England Biolabs, Ipswich, MA), Fu-
GENE 6 (Roche, Mannheim, Germany), Lipofectamine 2000
(Invitrogen), Metafectene (Biontex, Munich, Germany), and
Dreamfect (Oz Bioscience, Marseille, France) were used.
Cell Culture
Primary cells used in this study included lapine skeletal
muscle cells and articular chondrocytes and human cells
from fibrous dysplasia. Established cell lines were SAOS-2
(human osteosarcoma), CS-1 (human chondrosarcoma), L8
(murine skeletal myoblasts), and NIH 3T3 cells (murine
fibroblasts). Cells were cultured at 37C in a humidified
atmosphere with 5% CO2. Lapine articular chondrocytes
were obtained from cartilage of the knee joints of male
Chinchilla bastard rabbits as previously described [9]. La-
pine muscle was obtained from the quadriceps muscle of
male Chinchilla bastard rabbits. Pieces of 0.5 cm3 were
removed after sacrifice and transferred to a spinner bottle
containing DMEM with 50 lg/ml ascorbic acid, 100 U/ml
penicillin G and 100 ml/ml streptomycin (basal medium)
with collagenase (0.05%) for 20 h. Cells were filtered
through a 40-lm cell strainer to remove undigested matrix.
Cells from human fibrous dysplasia were obtained from
tissue removed during tumor surgery of the proximal femur
from a 23-year-old patient after digestion for 16 h in basal
medium containing 0.2% collagenase. All cells were placed
in monolayer culture in DMEM with 10% FBS (growth
medium) in 24-well plates. Transfections were performed at
60–70% cell confluence.
Plasmid DNA
Plasmid expression vectors carried either the Photinus
pyralis luciferase gene (pCMVLuc), the Escherichia coli
lacZ gene (pCMVlacZ) or the human IGF-I gene
(pCMVhIGF-I) under the control of the CMV-IE promoter/
enhancer. Vectors were propagated in competent E. coli
cells (TOP 10 One Shot, Invitrogen). Ultrapure endotoxin-
free plasmid DNA was prepared using the Qiagen Endofree
Plasmid Maxi Kit according to the manufacturer’s
instructions. Plasmid DNA was diluted in sterile water to a
final concentration of 1 lg/ll DNA.
Nonviral Gene Transfer
Prior to transfections monolayer cultures of cells in 24-well
plates were rinsed with phosphate-buffered saline (PBS,
PAA) and fresh growth medium was added to the cells. For
transfections with Escort III, basal medium was added
instead of growth medium. For transfections with Trans-
Pass D2, growth medium was removed and the transfection
complexes were directly added to the cells. All transfec-
tions were performed according to the manufacturer’s
instructions. Reagents were complexed to plasmid DNA in
sterile polypropylene tubes at room temperature.
Nanofectin 1 and 2
Nanofectin 1 and 2 are positively charged polymers with
DNA-binding capacity that are embedded into a porous
nanoparticle. For transfections, 1 lg DNA in 50 ll NaCl
(0.9%) was complexed with 3.2 ll Nanofectin 1 or 2 in
50 ll NaCl (0.9%) and added to the cells after 25 min.
Two hours later, 500 ll growth medium was added to the
complexes.
Superfect
This activated-dendrimer transfection reagent has a spher-
ical architecture with branches radiating from a central core
and terminating at positively charged amino groups. About
1 lg DNA was diluted in Opti-MEM to a total volume of
60 ll. Superfect transfection reagent (5 ll) was added.
Complexes were allowed to form for 10 min and added to
the cells. Two and a half hours later, the cells were washed
with PBS and fresh growth medium was added.
JetPEI
JetPEI consists of a linear polyethylenimine and compacts
the DNA into positively charged particles. Intracellularly,
it protects the DNA from degradation in endolysosomes by
buffering the endosomal pH. The DNA (1 lg) and 2 ll of
the JetPEI reagent were complexed in 50 ll NaCl (0.9%),
left to incubate for 25 min and added to the cells.
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Escort III
Escort III is a cationic liposome suspension in water,
composed of a polycationic lipid and a neutral lipid com-
pound. The DNA (0.3 lg) and the liposome suspension
(0.6 ll) were diluted in 20 ll Opti-MEM, combined,
allowed to form complexes for 30 min and then added to
the wells. After 6 h, basal medium containing 20% fetal
bovine serum (FBS) was added which was replaced by
growth medium after 18 h.
Gene Jammer
This formulation of polyamine and other components in
80% ethanol was diluted in 100 ll Opti-MEM and was
complexed with 1 lg DNA. Three hours after adding these
complexes, cells were washed and incubated with growth
medium. For transfections of lapine articular chondrocytes,
the volume of Gene Jammer reagent was varied between 3
and 12 ll (vector/DNA ratios of 3:1, 6:1, 9:1 and 12:1).
Exposure times tested ranged from 3 to 7 h.
Effectene
Effectene is a transfection system based on a non-liposo-
mal lipid. As a first step, 0.2 lg of the DNA was condensed
by interaction with a specific enhancer (1.6 ll) in a defined
buffer at a total volume of 60 ll. Afterwards, a volume of
5 ll of the Effectene reagent was added, complexes were
allowed to form for 5 min and added to the cells.
TransPass D2
TransPass D2 is based on a non-lipid cationic polymer.
DNA (0.3 lg) was complexed with 0.8 ll TransPass D2 in
300 ll Opti-MEM. Growth medium was removed from the
cells and the polymer/DNA complexes were added after an
incubation period of 25 min. Two and a half hours later,
the transfection solution was replaced by growth medium.
Metafectene
Metafectene is a polycationic transfection reagent based on
a liposome that enables destabilization of the lipid mem-
brane within the acidic endosomal environment by repul-
sive electrostatic forces. In 30 ll Opti-MEM each, 0.5 lg
plasmid DNA and 2.5 ll Metafectene were diluted, com-
bined, and then the complexes obtained were added to the
cells after 20 min. For lacZ transfections of NIH 3T3 cells,
in order to evaluate the optimal transfection conditions, the
volume of Metafectene ranged from 1 to 4 ll (vector/DNA
ratios of 2:1, 5:1 or 8:1).
FuGENE 6
FuGENE 6 is a proprietary, non-liposomal mixture of lip-
ids. FuGENE 6 and 1 lg of DNA were allowed to form
complexes in 90 ll Opti-MEM 15 min prior to addition to
the cells. For optimization studies, the volume of FuGENE
6 per lg of DNA was varied from 1 to 4 ll (exposure times
were of 24, 48 and 72 h).
Lipofectamine 2000
Lipofectamine 2000 is a novel proprietary cationic lipid
formulation. DNA (0.8 lg) and Lipofectamine 2000 (2 ll)
were diluted in 50 ll Opti-MEM each. After combining
these solutions, the complexes were allowed to form for
20 min and next added to the cells. Lipofectamine 2000
was optimized for transfections of cells from fibrous dys-
plasia and CS-1 cells. The volume of transfection reagent
varied between 1 and 3 ll. Vector/DNA ratios were of
1.25:1, 2.5:1, and 3.75:1.
Dreamfect
Dreamfect combines cationic lipids and polymers, resulting
in lipopolyamines, which contain a lipophilic part and a
charged polyamine moiety. Plasmid DNA (0.5 lg) was
complexed with 2 ll Dreamfect, diluted in 50 ll Opti-
MEM, incubated for 20 min, and added to the cells. The
transfection of lapine skeletal muscle cells was optimized
using Dreamfect. Dreamfect volumes were of 2, 4, and 6 ll
(vector/DNA ratios of 4:1, 8:1 and 12:1).
Calcium Phosphate Co-precipitates
Calcium phosphate co-precipitates were prepared by com-
bining 0.8 lg plasmid DNA in 22 ll 0.1 · TE with 25 ll of
2 · HEPES buffered saline [10]. CaCl2 (3.1 ll, 2 M) was
carefully added to this solution and the resulting complexes
were applied to the cells after 25 min of incubation.
Detection of Transgene Expression
Transgene Expression was detected at a standardized rep-
resentative time point of 48 h after transfection. Luciferase
activity using all 13 transfection systems was measured by
Mol Biotechnol (2008) 38:137–144 139
chemiluminescence (Luciferase Assay System; Promega,
Madison, WI) using a TECAN GENios microplate reader
(TECAN, Crailsheim, Germany). Sample light units (rela-
tive light units, RLU) were recorded in duplicates within 5 s
after addition of the substrate. Transfections using the E. coli
lacZ and the human IGF-I gene were carried out with the
most effective transfection system per cell type as deter-
mined by luciferase. Efficiencies were determined by X-gal
staining for 5 h at 37C of lacZ transfected and control cells
(b-Gal Staining Set; Roche) using a standard procedure as
previously described [3]. In order to determine the produc-
tion of IGF-I protein, the medium was replaced by basal
medium 1 day after transfection. After 24 h, the conditioned
medium was collected and subjected to ELISA (detection
limit: 0.03 ng/ml; R&D Systems, Minneapolis, MN).
Statistical Analysis
Data are expressed as mean ± standard deviation (s.d.) of
separate experiments. Luciferase transfections were inde-
pendently performed three to four times (n = 3 wells per
transfection reagent) for each cell type. Sample light units
(RLU) per well were recorded in duplicate. For lacZ
transfections, 3–5 independent optimization experiments
were carried out (n = 3 wells per condition). The IGF-I
transfection experiments were performed in duplicate
(n = 2 wells per condition). ANOVA was applied to
determine the significance of differences among groups. P
values less than 0.05 were considered significant.
Results
Primary Lapine Skeletal Muscle Cells
Out of the 13 transfection systems tested, Dreamfect and
Metafectene promoted maximal transgene expression as
determined by chemiluminescence (13,013 ± 593 and
12,519 ± 1,428 RLU, respectively; P = 0.73) (Fig. 1) vis-a-
vis all other reagents tested. In contrast, Escort III mediated the
minimal transgene expression; 30-fold lower than Dreamfect
(435 ± 21 RLU). Maximal gene expression was seen with
0.5 lg DNA at a (v/w) Dreamfect/DNA ratio of 4:1, corre-
sponding to a mean transfection efficiency of 60.8 ± 21.2%.
Increasing the lipid/DNA ratio (8:1; 12:1) led to decreased
efficiencies. IGF-I expression levels in IGF-I-transfected cells
using Dreamfect were of 142.3 ± 7.0 ng/106 cells/24 h, 285-
fold higher than in non-transfected cells (Table 1).
Primary Lapine Articular Chondrocytes
Gene Jammer, JetPEI and calcium phosphate co-precipitates
mediated the highest luciferase expression (22,806 ± 8,373,
22,347 ± 4,865 and 21,047 ± 8,653 RLU; P = 0.26)
(Fig. 1). Transfection with Nanofectin 2 resulted in the
lowest efficiency (1,296 ± 1,214 RLU). Maximal transgene
activity was obtained with 1 lg DNA at a (v/w) Gene Jam-
mer/DNA ratio of 3:1, corresponding to a transfection effi-
ciency of 38.9 ± 5.9%. Increasing the lipid/DNA ratio (6:1;
9:1; 12:1) led to decreased transfection efficiencies. Secre-
tion of IGF-I in Gene Jammer-transfected chondrocytes was
of 61.3 ± 12.0 ng/106 cells/24 h, 77-fold higher than in non-
transfected cells (0.8 ± 0.2 ng/106 cells/24 h).
Primary Cells from Human Fibrous Dysplasia
Lipofectamine 2000, JetPEI, Nanofectin 1, and TransPass
D2 achieved highest transgene expression (109 ± 111,
98 ± 111, 81 ± 63, 60 ± 71 RLU, respectively; P = 0.24).
Maximal transfection efficiency was 5.2 ± 8.0% (Lipo-
fectamine 2000; lipid/DNA ratio: 2.5:1). Other (3.75:1,
1.25:1) lipid/DNA ratios did not further increase
Fig. 1 Comparative analysis of transgene expression for primary
cells. Data are expressed as mean luciferase activity (relative light
units, RLU) per well ± standard deviation from at least three
independent experiments
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efficiencies. IGF-I secretion (Lipofectamine 2000) was 2.5-
fold higher than of non-transfected cells (P < 0.05).
Human Osteosarcoma Cells (SAOS-2)
Gene expression was maximal with FuGENE 6, JetPEI,
Gene Jammer, Metafectene, Dreamfect and calcium
phosphate co-precipitates (11,430 ± 9,480, 9,426 ± 7,887,
9,156 ± 6,606, 8,165 ± 4,692, 6,159 ± 4,360 and 5,924 ±
3,466 RLU, respectively; P = 0.08) (Fig. 2). Highest effi-
ciency of 12.7 ± 16.2% was seen at a FuGENE 6/DNA
ratio of 2:1. Ratios of 1:1, 3:1, and 4:1 did not led to further
increases. IGF-I secretion was 27.3 ± 7.1 ng/106 cells/
24 h, 23-fold higher than in non-transfected cells
(1.2 ± 0.2 ng/106 cells/24 h).
Human Chondrosarcoma Cells (CS-1)
Lipofectamine 2000, Gene Jammer, Nanofectin 1, and
FuGENE 6 led to the highest transgene expression
(8,470 ± 6,204, 7,482 ± 4,575, 5,354 ± 1,188, 5,197 ±
2,647 RLU, respectively; P = 0.12) (Fig. 2). Maximal
transfection efficiency was 30.0 ± 3.5% at a (v/w) Lipo-
fectamine/DNA ratio of 2.5:1. Higher (3.75:1) and lower
(1.25:1) ratios did not result in higher transfection effi-
ciencies. IGF-I expression levels were of 37.9 ± 8.8 ng/
106 cells/24 h, 29-fold higher than in non-transfected cells
(1.3 ± 0.3 ng/106 cells/24 h).
Murine Skeletal Myoblasts (L8)
FuGENE 6, TransPass D2 and Nanofectin 1 produced
maximal transgene expression (38,882 ± 16,729, 14,490
± 5,937, 11,271 ± 527 RLU, respectively; P = 0.07)
(Fig. 2) with an efficiency of 64.6 ± 14.2% (FuGENE 6).
Secretion of IGF-I was 179.2 ± 5.7 ng/106 cells/24 h,
almost 200-fold higher than in non-transfected cells
(Table 1).
Murine Fibroblasts (NIH 3T3)
Luciferase expression was the highest with Metafectene
and Nanofectin 1 (45,370 ± 25,958 and 44,065 ±
17,745 RLU, respectively; P = 0.84) (Fig. 2). Maximal
efficiency was 48.9 ± 13.0% (Metafectene; lipid/DNA
ratio: 5:1). Lower (2:1) or higher lipid/DNA ratios (8:1) led
to decreased efficiencies. IGF-I expression levels were
84.2 ± 16.9 ng/106 cells/24 h, 70-fold higher than in non-
transfected cells (1.2 ± 0.1 ng/106 cells/24 h) (Table 1).T
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Discussion
The present study comparatively analyzed the efficacy of
transfection of 13 novel nonviral transfection systems in
cells of musculoskeletal origin. The data indicate that
relatively high levels of transfection can be achieved in
primary cultures of lapine skeletal muscle cells and articular
chondrocytes, as well as in established cell lines such as L8
(muscle cells), CS-1 (chondrosarcoma) and NIH 3T3 cells
(fibroblasts). The data further demonstrates that human
osteosarcoma (SAOS-2) cells and cells from human fibrous
dysplasia can be transfected at lower efficiencies. Finally,
the data suggest that significant amounts of human IGF-I, a
potential therapeutic candidate, can be produced in primary
lapine muscle cells and chondrocytes, L8, and NIH 3T3
cells. The results obtained using three genes (luc, lacZ, IGF-
I) indicate that the nature of the cell itself is a critical factor
that determines the level of gene expression following
transfection. Therefore, it is important to carefully charac-
terize the most suitable transfection system for each cell
type prior to functional studies in order to achieve maximal
transgene expression.
Transfection efficiencies for muscle cells have been
previously reported to be in the range of 0–70%, e.g.,
using LipofectAmine and DOSPER in human myoblast
clones [11], DAC-40 or Effectene in human skeletal
muscle cells [12], complexes of adenovirus particles with
cationic lipids and polymers in murine muscle cells [13]
or Lipofectamine and DOTAP in primary cultures of
murine myoblasts [14]. In the present study, efficiencies in
lapine skeletal muscle cells were 61% using Dreamfect
and 65% in the myoblast cell line L8 using FuGENE 6.
Comparable high levels of transgene expression in a
myoblast cell line have been achieved to date only using
high-titer retroviral vectors [15].
The reported efficiencies in lapine articular chondro-
cytes of 39% using the cationic liposome formulation
Gene Jammer correspond well to the 40% transfection
efficiencies that were previously reported [3]. Since, the
data from this study were obtained after additional treat-
ment of the cells with hyaluronidase prior to and during
transfection, it is possible that the reported transfection
efficiencies may be further increased by such enzymatic
treatment aimed at partially removing the extracellular
matrix [3].
Transfection of primary cells from human fibrous
dysplasia was difficult to achieve. Maximal efficiency was
of 5.2%, obtained with Lipofectamine 2000. Yet, even
such relatively low efficiencies may result in possible
therapeutic effects, since studies overexpressing growth
factors in the arterial wall showed that efficiencies of less
than 1% were sufficient to achieve a biological effect
in vivo [16]. Osteosarcoma (SAOS-2) cells were trans-
fected with an efficiency of 13% using FuGENE 6 fol-
lowing optimization. Nonviral transfection of SAOS-2
cells was reported only rarely [17] and transfection effi-
ciencies have not yet been reported to date. For human
chondrosarcoma CS-1 cells, the cationic liposome Lipo-
fectamine 2000 mediated the highest efficiencies. Com-
parable transfection efficiencies (30%) using non-viral
systems for this cell line and other chondrosarcoma cells
have, to our best knowledge, not been demonstrated to
Fig. 2 Comparative analysis of transgene expression for established
cell lines. Data are expressed as mean luciferase activity (relative
light units, RLU) per well ± standard deviation
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date. High transfection efficiency is a basis for successful
application of gene-based treatments of musculoskeletal
tumors.
NIH 3T3 cells have been previously transfected with
various nonviral transfection reagents, including Lipofec-
tamine and DOSPER [18], Effectene and Superfect [19],
LipofectAMINE PLUS [20] or FuGENE 6 [21]. While
transfection efficiencies were less than 30% in these stud-
ies, the present data indicate that transfection efficiencies
of almost 50% can be achieved with Metafectene, a cat-
ionic liposome formulation.
Interestingly, the calcium phosphate co-precipitation
method promoted high transfection efficiencies in primary
lapine articular chondrocytes and SAOS-2 cells, statisti-
cally not different from those mediated by commercially
available reagents. With regard to its low cost and simple
and reproducible production, the calcium phosphate trans-
fection thus represents an attractive alternative.
We have selected the human IGF-I gene as an additional
candidate because of potential applications in the therapy of
musculoskeletal diseases. For example, IGF-I prevents mus-
cle atrophy [22], stimulates cutaneous wound healing [23] and
enhances articular cartilage repair [9, 24]. In the present study,
IGF-I expression levels were between 27 and 240 ng/
106 cells/24 h, depending on the cell type, except for cells of
fibrous dysplasia. Transfections of lapine articular chondro-
cytes resulted in IGF-I production of 61 ng/106 cells/24 h, i.e.
7-fold higher than the 8.3 ng/106 cells/24 h previously
reported for bovine articular chondrocytes [25]. In L8 cells,
FuGENE 6 mediated the highest transfection efficiency (65%)
and maximal IGF-I production (179.2 ± 5.7 ng/106 cells/
24 h) among all the transfection systems used. A bovine
mammary epithelial cell line secreted 9.2 ng IGF-I/106 cells/
24 h following selection for cells carrying the transgene [26].
Retroviral gene transfer and selection of transduced cells
resulted in 56 ng IGF-I/106 keratinocytes/24 h [27]. These
data show that cells from different musculoskeletal origin can
be transfected with optimized systems to produce significant
amounts of a secreted recombinant protein that are sufficient
to mediate a therapeutic effect [9, 24, 25].
Taken together, our results indicate that novel lipid-
based methods can be sufficiently optimized to offer a
feasible approach for gene delivery into a wide range of
cells. The described techniques might be of potential value
for functional gene analyses and for gene therapy approa-
ches in tissue engineering and the treatment of musculo-
skeletal disorders.
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